1764 – Micro-bypass glaucoma surgery device implantation into the suprachoroidal space as a standalone procedure in patients with open angle glaucoma

New MBS item.

Reduction of intraocular pressure is the only known modifiable glaucoma risk factor. Micro-bypass glaucoma surgery can be used to reduce intraocular pressure in open angle glaucoma (in patients with no current cataract co-morbidity or patients who have already undergone cataract surgery) following failure or intolerance to more conservative therapies (medication to reduce intraocular pressure and laser trabeculoplasty) when the patient is a candidate for incisional surgery. MINIject micro-bypass stent system can be inserted into the suprachoroidal space during micro-bypass surgery to enhance drainage of aqueous outflow into the suprachoroidal space to reduce intraocular pressure, reducing reliance on topical hypotensive medication.

Type: Therapeutic technology

Glaucoma is a group of complex eye diseases leading to chronic and progressive damage to the optic nerve and progressive, irreversible vision loss. It is a major public health problem, as glaucoma is the leading cause for irreversible visual impairment and the second leading cause for blindness worldwide. Reduction of intraocular pressure is the only known modifiable glaucoma risk factor that can reduce progressive loss of vision and is associated with improved health outcomes including reduced visual loss and improvements in quality of life.

• PASC consultation: Not applicable
• MSAC consultation: Closed Friday 16 February 2024

• PASC meeting: Expedited - bypassed PASC
• ESC meeting: 15–16 February 2024
• MSAC meeting: 4–5 April 2024